Masha V. Poyurovsky

Masha V. Poyurovsky

Auto-generated profile, based on publicly available information

Masha V. Poyurovsky

PMV Pharmaceuticals, Inc. (United States) 1 Princeton, NJ

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Cell Chemical Biology
Verified
Journal Article
Open access
KOKellen Olszewski
Kellen Olszewski
ABAnthony Barsotti
Anthony Barsotti
XFXiao-Jiang Feng
Xiao-Jiang Feng
MMMilica Momcilovic
Milica Momcilovic
KLKevin G. Liu
Kevin G. Liu
MPMasha V. Poyurovsky
Masha V. Poyurovsky
Efforts to target glucose metabolism in cancer have been limited by the poor potency and specificity of existing anti-glycolytic agents and a poor understanding of the glucose dependence of cancer subtypes in vivo. Here, we present an extensively characterized series of potent, orally bioavailable inhibitors of the class I glucose transporters (GLUTs). The representative compound KL-11743 specifically blocks glucose metabolism, triggering an acute collapse in NADH pools and a striking accumulation of aspartate, indicating a dramatic shift toward oxidative phosphorylation in the mitochondria. Disrupting mitochondrial metabolism via chemical inhibition of electron transport, deletion of the malate-aspartate shuttle component GOT1, or endogenous mutations in tricarboxylic acid cycle enzymes, causes synthetic lethality with KL-11743. Patient-derived xenograft models of succinate dehydrogenase A (SDHA)-deficient cancers are specifically sensitive to KL-11743, providing direct evidence that TCA cycle-mutant tumors are vulnerable to GLUT inhibitors in vivo.

14 February 2025 in Cancer Discovery
Verified
Journal Article
Open access
APAnna M. Puzio-Kuter
Anna M. Puzio-Kuter
LXLizhong Xu
Lizhong Xu
MMMary Kate McBrayer
Mary Kate McBrayer
RDRomyr Dominique
Romyr Dominique
HLHongju H. Li
Hongju H. Li
MPMasha V. Poyurovsky
Masha V. Poyurovsky
Restoration of the tumor suppressor function of tumor-associated p53 mutants, including the Y220C substitution, has posed a significant challenge for therapeutic discovery. In this study, we describe rezatapopt (PC14586), part of a series of compounds designed to reactivate the p53 Y220C mutant. These compounds restore p53 tumor suppressor function by correcting its conformation and enabling it to bind DNA and activate downstream target genes, thus inducing antiproliferative changes in tumor cells. Our findings are supported by biochemical and structural analysis, in vitro and in vivo transcriptomics, and functional data, revealing the recovery of multiple aspects of the wild-type p53 program. These compounds demonstrate potent antitumor activity in preclinical models as single agents and in combination with immunotherapy. Currently, rezatapopt is being evaluated in a registrational phase II clinical trial for patients with advanced solid tumors harboring the TP53 Y220C mutation. Significance: Rezatapopt is a clinical-stage compound that offers a promising treatment option for TP53-mutant cancers. This study details the characterization of rezatapopt and its related compounds, which can reinstate the tumor suppressor activity of the p53 Y220C mutant. These results emphasize the potential for targeting p53 mutations in cancer therapy.

29 October 2010 in Cell Cycle
Verified
Journal Article
Closed access
PDF file
MPMelissa J. Peart
Melissa J. Peart
MPMasha V. Poyurovsky
Masha V. Poyurovsky
EKElizabeth M. Kass
Elizabeth M. Kass
MUMarshall Urist
Marshall Urist
EVEmmy Verschuren
Emmy Verschuren
CPCarol Prives
Carol Prives
The mechanisms that control E2F-1 activity are complex. We previously showed that Chk1 and Chk2 are required for E2F1 stabilization and p73 target gene induction following DNA damage. To gain further insight into the processes regulating E2F1 protein stability, we focused our investigation on the mechanisms responsible for regulating E2F1 turnover. Here we show that E2F1 is a substrate of the anaphase promoting complex or cyclosome (APC/C), a ubiquitin ligase that plays an important role in cell cycle progression. Ectopic expression of the APC/C activators Cdh1 and Cdc20 reduced the levels of co-expressed E2F-1 protein. Co-expression of DP1 with E2F1 blocked APC/C-induced E2F1 degradation, suggesting that the E2F1/DP1 heterodimer is protected from APC/C regulation. Following Cdc20 knockdown, E2F1 levels increased and remained stable in extracts over a time course, indicating that APC/CCdc20 is a primary regulator of E2F1 stability in vivo. Moreover, cell synchronization experiments showed that siRNA directed against Cdc20 induced an accumulation of E2F1 protein in prometaphase cells. These data suggest that APC/CCdc20 specifically targets E2F1 for degradation in early mitosis and reveal a novel mechanism for limiting free E2F1 levels in cells, failure of which may compromise cell survival and/or homeostasis.

2 March 2024 in Protein & Cell
Verified
Journal Article
Open access
PDF file
XLXiaoguang Liu
Xiaoguang Liu
ZCZhen Chen
Zhen Chen
YYYuelong Yan
Yuelong Yan
FZFereshteh Zandkarimi
Fereshteh Zandkarimi
LNLitong Nie
Litong Nie
BGBoyi Gan
Boyi Gan
Ferroptosis has been recognized as a unique cell death modality driven by excessive lipid peroxidation and unbalanced cellular metabolism. In this study, we established a protein interaction landscape for ferroptosis pathways through proteomic analyses, and identified choline/ethanolamine phosphotransferase 1 (CEPT1) as a lysophosphatidylcholine acyltransferase 3 (LPCAT3)-interacting protein that regulates LPCAT3 protein stability. In contrast to its known role in promoting phospholipid synthesis, we showed that CEPT1 suppresses ferroptosis potentially by interacting with phospholipases and breaking down certain pro-ferroptotic polyunsaturated fatty acid (PUFA)-containing phospholipids. Together, our study reveals a previously unrecognized role of CEPT1 in suppressing ferroptosis.

27 September 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
MMMeghan Mooring
Meghan Mooring
GYGrace A. Yeung
Grace A. Yeung
PLPanu Luukkonen
Panu Luukkonen
Silvia LiuSilvia Liu
Silvia Liu
MAMuhammad Waqas Akbar
Muhammad Waqas Akbar
DYDean Yimlamai
Dean Yimlamai
Obesity is increasing worldwide and leads to a multitude of metabolic diseases, including cardiovascular disease, type 2 diabetes, nonalcoholic fatty liver disease, and nonalcoholic steatohepatitis (NASH). Cysteine-rich angiogenic inducer 61 (CYR61) is associated with the progression of NASH, but it has been described to have anti- and proinflammatory properties. We sought to examine the role of liver CYR61 in NASH progression. CYR61 liver-specific knockout mice on a NASH diet showed improved glucose tolerance, decreased liver inflammation, and reduced fibrosis. CYR61 polarized infiltrating monocytes promoting a proinflammatory/profibrotic phenotype through an IRAK4/SYK/NF-κB signaling cascade. In vitro, CYR61 activated a profibrotic program, including PDGFa/PDGFb expression in macrophages, in an IRAK4/SYK/NF-κB–dependent manner. Furthermore, targeted-antibody blockade reduced CYR61-driven signaling in macrophages in vitro and in vivo, reducing fibrotic development. This study demonstrates that CYR61 is a key driver of liver inflammation and fibrosis in NASH.

1 February 2009 in Cell Cycle
Verified
Journal Article
Closed access
PDF file
EKElizabeth M. Kass
Elizabeth M. Kass
MPMasha V. Poyurovsky
Masha V. Poyurovsky
YZYan Zhu
Yan Zhu
CPCarol Prives
Carol Prives
We have previously shown that Chk2 stability, which is increased after DNA damage in some cells, is regulated in part through phosphorylation at S456 and that a mutant Chk2 (S456A) is hyperubiquitinated and turned over more rapidly than wild-type Chk2. (Kass J. Biol Chem 2007) Here we show that the S456A mutant preferentially binds to Mdm2 compared to wild-type Chk2 and down-regulation of Mdm2 with siRNA can rescue the observed destabilization of S456A Chk2 following DNA damage. Ubiquitination of wild-type Chk2 is increased by co-expression of Mdm2, and increasing amounts of Mdm2 enhance degradation of both wild-type and mutant S456A Chk2. Surprisingly, however, an E3 ligase defective version of Mdm2 (ΔC7) also increases ubiquitination and degradation of Chk2 when transfected into cells, suggesting that the ability of Mdm2 to affect Chk2 turnover is independent of its intrinsic E3 ligase function. Recently the acetyltransferase PCAF was shown to have intrinsic E3 ligase activity against itself and Mdm2. We found that PCAF interacts with both Mdm2 and Chk2 and that PCAF increases Chk2 ubiquitination and degradation. Interestingly as well, a PCAF deletion mutant that lacks E3 ligase activity towards Mdm2 also enhances Chk2 degradation. We hypothesize that Mdm2 and PCAF may function as part of a multi-subunit E3 complex in their regulation of Chk2 turnover.